The significance of homocysteine in patients with hypertension
By:
References
- Zdrojewski T., Szpakowski B., Bandosz P., Pająk A., Więcek A., Krupa-Wojciechowska B., Wyrzykowski B.: Arterial hypertension in Poland 2002. J. Hum. Hypertens., 2004, 18: 557–562
- Whelton P.K., Carey R.M., Aronow W.S., Casey D.E. Jr, Collins K.J., Dennison Himmelfarb C., DePalma S.M., Gidding S., Jamerson K.A., Jones D.W., et al.: 2017 ACC/AHA/AAPA/ABC/ACPM/ AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension, 2018; 71: 1,269–1,324
- Lawes C.M., Vander Hoorn S., Rodgers A., International Society of Hypertension: Global burden of blood pressure-related disease, 2001. Lancet, 2008; 371: 1,513–1,518
- Tykarski A., Filipiak K.J., Januszewicz A., Litwin M., Narkiewicz K., Prejbisz A, Ostalska-Nowicka D., Widecka K., Kostka-Jeziorny K.: Guidelines of the Polish Society of Hypertertension 2019. Arterial Hypertens., 2019; 23: 41–87
- McCully K.S.: Homocysteine and the pathogenesis of atherosclerosis. Expert Rev. Clin. Pharmacol., 2015; 8: 211–219
- Castro R., Rivera I., Blom H.J., Jakobs C., Tavares de Almeida I.: Homocysteine metabolism, hyperhomocysteinaemia and vascular disease: An overview. J. Inherit. Metab. Dis., 2006; 29: 3–20
- Kumar A., Palfrey H.A., Pathak R., Kadowitz P.J., Gettys T.W., Murthy S.N.: The metabolism and significance of homocysteine in nutrition and health. Nutr. Metab., 2017; 14: 78
- Hankey G.J.: B vitamins for stroke prevention. Stroke Vasc. Neurol., 2018; 3: 51–58
- Waśkiewicz A., Sygnowska E., Broda G.: Dietary intake of vitamins B6, B12 and folate in relation to homocysteine serum concentration in the adult Polish population – WOBASZ Project. Kardiol Pol., 2010; 68: 275–282
- Fan R., Zhang A., Zhong F.: Association between homocysteine levels and all-cause mortality: A dose-response meta-analysis of prospective studies. Sci. Rep., 2017; 7: 4,769
- Waśkiewicz A., Sygnowska E., Broda G.: Homocysteine concentration and the risk of death in the adult Polish population. Kardiol. Pol., 2012; 70: 897–902
- Strauss E., Supiński W., Radziemski A., Oszkinis G., Pawlak A.L., Głuszek J.: Is hyperhomocysteinemia a causal factor for heart failure? The impact of the functional variants of MTHFR and PON1 on ischemic and non-ischemic etiology. Int. J. Cardiol., 2017; 228: 37–44
- Kong X., Ma X., Zhang C., Su H., Xu D.: Hyperhomocysteinemia increases the risk of chronic kidney disease in a Chinese middle-aged and elderly population-based cohort. Int. Urol. Nephrol., 2017; 49: 661–667
- Homocysteine Studies Collaboration: Homocysteine and risk of ischemic heart disease and stroke: A meta-analysis. JAMA, 2002; 288: 2015–2022
- Wald D.S., Law M., Morris J.K.: Homocysteine and cadiovascular disease: Evidence on causality from a meta-analysis. BMJ, 2002; 325: 1202
- Baszczuk A., Kopczyński Z., Thielmann A.: Endothelial dysfunction in patients with primary hypertension and hyperhomocysteinemia. Postępy Hig. Med. Dośw., 2014; 68: 91–100
- Lai W.K., Kan M.Y.: Homocysteine-induced endothelial dysfunction. Ann. Nutr. Metab. 2015; 67: 1–12
- Cheng Z., Yang X., Wang H.: Hyperhomocysteinemia and endothelial dysfunction. Curr. Hypertens. Rev., 2009; 5: 158–165
- James S.J., Melnyk S., Pogribna M., Pogribny I.P., Caudill M.A.: Elevation in S-adenosylhomocysteine and DNA hypomethylation: Potential epigenetic mechanism for homocysteine-related pathology. J. Nutr.. 2002; 132: 2,361S–2,366S
- Brzezińska A., Balińska M.: Rola homocysteiny w procesie rozwoju zmian miażdżycowych na poziomie komórkowym. Postępy Biol. Kom., 2000; 27: 81–96
- Tsai J.C., Kuo H.T., Chiu Y.W., Hwang S.J., Chuang H.Y., Chang J.M., Chen H.C., Lai Y.H.: Correlation of plasma homocysteine level with arterial stiffness and pulse pressure in hemodialysis patients. Atherosclerosis, 2005; 182: 121–127
- Sen U., Mishra P.K., Tyagi N., Tyagi S.C.: Homocysteine to hydrogen sulfide or hypertension. Cell Biochem. Biophys., 2010; 57: 49–58
- Dinavahi R., Cossrow N., Kushner H., Falkner B.: Plasma homocysteine concentration and blood pressure in young adult African Americans. Am. J. Hypertens., 2003; 16: 767–770
- Jacques P.F., Bostom A.G., Wilson P.W., Rich S., Rosenberg I.H., Selhub J.: Determinants of plasma total homocysteine concentration in the Framingham Offspring cohort. Am. J. Clin. Nutr., 2001; 73: 613–621
- Sundström J., Sulivan L., D`Agostino R.B., Jacques P.F., Selhub J., Rosenberg I.H., Wilson P.W., Levy D., Vasan R.S.: Plasma homocysteine, hypertension incidence, and blood pressure tracking: The Framingham Heart Study. Hypertension, 2003; 42: 1,100–1,105
- Cai W., Yin L., Yang F., Zhang L., Cheng J.: Association between Hcy levels and the CBS844ins68 and MTHFR C677T polymorphisms with essential hypertension. Biomed. Rep., 2014; 2: 861– 868
- Golbahar J., Mostafavi E.: Association between low red blood cell 5-methyltetrahydrofolate and hyperhomocysteinaemia with hypertension: A cross-sectional study. High Blood Press Cardiovasc. Prev., 2012; 19: 229-235
- Muda P., Kampus P., Zilmer M., Zilmer K., Kairane C., Ristimäe T., Fischer K., Teesalu R.: Homocysteine and red blood cell glutathione as indices for middle-aged untreated essential hypertension patients. J. Hypertens., 2003; 21: 2,329– 2,333
- Kahleová R., Palyzová D., Zvára K., Zvárová J., Hrach K., Nováková I., Hyánek J., Bendlová B., Kozich V.: Essential hypertension in adolescents: Association with insulin resistance and with metabolism of homocysteine and vitamins. Am. J. Hypertens., 2002; 15: 857–864
- Sutton-Tyrrell K., Bostom A., Selhub J., Zeigler-Johnson C.: High homocysteine levels are independently related to isolated systolic hypertension in older adults. Circulation, 1997; 96: 1,745–1,749
- Nygård O., Refsum H., Ueland P.M., Vollset S.E.: Major lifestyle determinants of plasma total homocysteine distribution: The Hordaland Homocysteine Study. Am. J. Clin. Nutr., 1998; 67: 263–270
- Kennedy B.P., Farag N.H., Ziegler M.G., Mills P.J.: Relationship of systolic blood pressure with plasma homocysteine: Importance of smoking status. J. Hypertens., 2003; 21: 1,307–1,312
- Neugebauer S., Tarnow L., Stehouwer C., Teerlink T., Baba T., Watanabe T., Parving H.H.: Total plasma homocysteine is associated with hypertension in type I diabetic patients. Diabetologia, 2002; 45: 1,315–1,324
- Mizrahi E.H., Noy S., Sela B.A., Fleissig Y., Arad M., Adunsky A.: Further evidence of interrelation between homocysteine and hypertension in, stroke patients: A cross-sectional study. Israel Med. Assoc. J., 2003; 5: 791–794
- Nigwekar S.U., Kang A., Zoungas S., Cass A., Gallagher M.P., Kulshrestha S., Navaneethan S.D., Perkovic V., Strippoli G.F., Jardine M.J.: Interventions for lowering plasma homocysteine levels in dialysis patients. Cochrane Database Syst. Rev., 2016; 2,016: CD004683
- Lim U., Cassano P.A.: Homocysteine and blood pressure in the Third National Health and Nutrition Examination Survey, 1,988– 1,994. Am. J. Epidemiol., 2002; 156: 1105-1113
- Han L., Liu Y., Wang C., Tang L., Feng X., Astell-Burt T., Wen Q., Duan D., Lu N., Xu G., et al.: Determinants of hyperhomocysteinemia in healthy and hypertensive subjects: A population-based study and systematic review. Clin. Nutr., 2017; 36: 1,215–1,230
- Borges M.C., Hartwig F.P., Olivera I.O., Horta B.L.: Is there a causal role for homocysteine concentration in blood pressure? A Mandelian randomization study. Am. J. Clin. Nutr., 2016; 103: 39–49
- Skeete J., DiPette D.J.: Relationship between homocysteine and hypertension: New data add to the debate. J. Clin. Hypertens., 2017; 19: 1,171–1,172
- Fakhrzadeh H., Ghotbi S., Pourebrahim R., Heshmat R., Nouri M., Shafaee A., Larijani B.: Plasma homocysteine concentration and blood pressure in healthy Iranian adults: The Tehran Homocysteine Survey (2003–2004). J. Hum. Hypertens., 2005; 19: 869–876
- Tian T., Yang K.Q., Cui J.G., Zhou L.L., Zhou X.L.: Folic acid supplementation for stroke prevention in patients with cardiovascular disease. Am. J. Med. Sci., 2017; 354: 379–387
- Bortolotto L.A., Safar M.E., Billaud E, Lacroix C., Asmar R., London G.M., Blacher J.: Plasma homocysteine, aortic stiffens, and renal function in hypertensive patients. Hypertension, 1999; 34: 837–842
- Liu X., Sun N., Yu T., Fan F., Zheng M., Qian G., Wang B., Wang Y., Tang G., Li J., et al.: The independent and joint association of blood pressure, serum total homocysteine, and fasting serum glucose levels with brachial-ankle pulse wave velocity in Chinese hypertensive adults. Int. Heart J., 2016; 57: 627–633
- Momin M., Fan F., Li J., Qin X., Jia J., Qi L., Zhang Y., Huo Y.: Associations of plasma homocysteine levels with peripheral systolic blood pressure and noninvasive central systolic blood pressure in a community-based Chinese population. Sci. Rep., 2017; 7: 6,316
- Wang X.N., Ye P., Cao R.H., Yang X., Xiao W.K., Zhang Y., Bai Y.Y., Wu H.M.: Plasma homocysteine is a predictive factor for arterial stiffness: A community-based 4.8-year prospective study. J. Clin. Hypertens., 2015; 17: 594–600
- Sun F., Qian W., Zhang C.H., Fan J.X., Feng H.F.: Correlation of maternal serum homocysteine in first trimester with the development of gestational hypertension and preeclampsia. Med. Sci. Monit., 2017; 23: 5,396–5,401
- Curgunlu A., Karter Y., Uzun H., Aydin S., Ertürk N., Vehid S., Simsek G., Kutlu A., Oztürk E., Erdine S.: Hyperhomocysteinemia: An additional risk factor in white coat hypertension. Int. Heart J., 2005; 46: 245–254
- Coban E., Ozdoğan M., Ermiş C.: Plasma levels of homocysteine in patients with white-coat hypertension. Int. J. Clin. Pract., 2004; 58: 997–999
- Pierdomenico S.D., Bucci A., Lapenna D., Lattanzio F.M., Talone L., Cuccurullo F., Mezzetti A.: Circulating homocysteine levels in sustained and white coat hypertension. J. Hum. Hypertens., 2003; 17: 165–170
- Yücel K., Bekçi T.T., Taner A., Kayrak M., Korucu E.N., Ünlü A.: Homocysteine levels in patients with masked hypertension. Anadolu Kardiyol. Derg., 2014; 14: 357–362
- Homocysteine Lowering Trialists’ Collaboration: Lowering blood homocysteine with folic acid based supplements: Meta-analysis of randomised trials. BMJ, 1998; 316: 894–898
- Mangoni A.A., Sherwood R.A., Swift C.G., Jackson S.H.: Folic acid enhances endothelial function and reduces blood pressure in smokers: A randomized controlled trial. J. Intern. Med., 2002; 252: 497–503
- Tamai Y., Wada K., Tsuji M., Nakamura K., Sahashi Y., Watanabe K., Yamamoto K., Ando K., Nagata C.: Dietary intake of vitamin B12 and folic acid is associated with lower blood pressure in Japanese preschool children. Am. J. Hypertens., 2011; 24: 1,215–1,221
- McRae M.P.: High-dose folic acid supplementation effects on endothelial function and blood pressure in hypertensive patients: A meta-analysis of randomized controlled clinical trials. J. Chiropr. Med., 2009: 8: 15–24
- Qin X., Li Y., Sun N., Wang H., Zhang Y., Wang J., Li J., Xu X., Liang M., Nie J., et al.: Elevated homocysteine concentrations decrease the antihypertensive effect of angiotensin-converting enzyme inhibitors in hypertensive patients. Arterioscl. Thromb. Vasc. Biol., 2017; 37: 166–172
- Wang W.W., Wang X.S., Zhang Z.R., He J.C., Xie C.L.: A meta-analysis of folic acid in combination with anti-hypertension drugs in patients with hypertension and hyperhomocysteinemia. Front. Pharmacol., 2017; 8: 585
- Sarigianni M., Dimitrakopoulos K., Tsapas A.: Non-dipping status in arterial hypertension: An overview. Curr. Vasc. Pharmacol., 2014; 12: 527–536
- Korkmaz S., Yilmaz A., Yildiz G., Kiliçli F., Içağasioğlu S.: Relationship between homocysteine and non-dipper pattern in patients with type 2 diabetes mellitus. Arg. Bras. Endocrinol Metab., 2012; 56: 285–290
- Cagnacci A., Cannoletta M., Volpe A.: High-dose short-term folate administration modifies ambulatory blood pressure in post menopausal women. Placebo-controlled study. Eur. J. Clin. Nutr., 2009; 63: 1,266–1,268
- Cagnacci A., Cannoletta M., Xholi A., Piacenti I., Palma F., Palmieri B.: Folate administration decrease oxidative status and blood pressure in postmenopausal women. Eur. J. Nutr., 2015; 54: 429– 435
- Dong Y.F., Zhan B.M., Hao Q.Y, Ruan Z.H., Xu Z.X., Deng M., Chen D.W., Zou Y.Q., Chen J., Li P., et al.: Plasma homocysteine levels are associated with circadian blood pressure variation in Chinese hypertensive adults. Am. J. Hypertens., 2017; 30: 1,203– 1,210
- Joyeux-Faure M., Baguet J.P., Barone-Rochette G., Faure P., Sosner P., Mounier-Vehier C., Lévy P., Tamisier R., Pépin J.L.: Continuous positive airway pressure reduces night-time blood pressure and heart rate in patients with obstructive sleep apnea and resistant hypertension: The RHOOSAS Randomized Controlled Trial. Front. Neurol., 2018; 9: 318
- Bønaa K.H., Njølstad I., Ueland P.M. Schirmer H., Tverdal A., Steigen T., Wang H., Nordrehaug J.E., Arnesen E., Rasmussen K.: Homocysteine lowering and cardiovascular events after acute myocardial infarction. N. Engl. J. Med., 2006; 354: 1,578–1,588
- VITATOPS Trial Study Group: B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: A randomised, double-blind, parallel, placebo-controlled trial. Lancet Neurol, 2010; 9: 855–865
- Saposnik G., Ray J.G., Sheridan P., McQueen M., Lonn E., Heart Outcomes Prevention Evaluation 2 Investigators: Homocysteinelowering therapy and stroke risk, severity, and disability: Additional findings from the HOPE 2 trial. Stroke, 2009; 40: 1,365–1,372
- Huo Y., Li J., Qin X., Huang Y., Wang X., Gottesman R.F., Tang G., Wang B., Chen D., He M., et al.: Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: The CSPPT randomized clinical trial. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: The CSPPT randomized clinical trial. JAMA, 2015; 313:1,325–1,335
- Qin X., Li J., Spence J.D., Zhang Y., Li Y., Wang X., Wang B., Sun N., Chen F., Guo J., et al.: Folic acid therapy reduces the firs stroke risk associated with hypercholesterolemia among hypertensive patients. Stroke, 2016; 47: 2,805–2,812
- Li K., Zhang J., Qin Y., Wei Y.X.: Association between serum homocysteine level and obstructive sleep apnea: A meta-analysis. Biomed. Res. Int., 2017; 2017: 7234528
- Tao L.H., Yang K., Wu J., Mahara G., Zhang J., Zhang J.B., Ping Z., Guo X.: Association between plasma homocysteine and hypertension: Results from a cross-sectional and longitudinal analysis in Beijing adult population from 2012–2017. J. Clin. Hypertens., 2018; 20: 1,624–1,632
- Zhao M., Wu G., Li Y., Wang X., Hou F.F., Xu X., Qin X., Cai Y.: Meta-analysis of folic acid efficacy trials on stroke prevention: Onsight into effect modifiers. Neurology, 2017; 88: 1,830–1,838
- Xu R.B., Kong X., Xu B.P., Song Y., Ji M., Zhao M., Huang X., Li P., Cheng X., Chen F., et al:. Longitudinal association between fasting blood glucose concentrations and first stroke in hypertensive adults in China: Effect of folic acid intervention. Am. J. Clin. Nutr., 2017; 105: 564–570
- Meng Y., Li J., Chen X., She H., Zhao L., Peng Y., Zhang J., Shang K., Li H Yang W., et al.: Association between folic acid suplementation and retinal atherosclerosis in Chinese adults with hypertension complicated by diabetes mellitus. Front. Pharnacol., 2018; 9: 1,159
- Li Y., Liang M., Wang G., Wang B., He M., Tang G., Yin D., Xu X., Huo Y., Cui Y., et al.: Effects of folic acid therapy on the new-onset proteinuria in Chinese hypertensive patients: A post analysis of the renal substudy of CSPPT (China Stroke Primary Prevention Trial). Hypertension, 2017; 70: 300–306
- Li Y., Qin X., Luo L., Wang B., Huo Y., Hou, F.F., Xu X.: Folic acid therapy reduces the risk of mortality associated with heavy proteinuria among hypertensive patients. J. Hypertens., 2017; 35: 1,302–1,309
- Bravo-Soto G.A., Madrid T.: Is folic acid supplementation useful for chronic kidney disease? Medwave, 2016; 16: e6,591
- Qin X., Huo Y., Xie D., Hou F., Xu X., Wang X.: Homocysteinelowering therapy with folic acid is effective in cardiovascular disease prevention in patients with kidney disease: A meta-analysis of randomized controlled trials. Clin Nutr., 2013; 32: 722–727
DOI: https://doi.org/10.2478/ahem-2021-0002 | Journal eISSN: 1732-2693
Language: English
Page range: 634 - 642
Submitted on: May 28, 2020
Accepted on: Feb 26, 2021
Published on: Oct 21, 2021
Published by: Hirszfeld Institute of Immunology and Experimental Therapy
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
Related subjects:
© 2021 Jerzy Gluszek, Teresa Kosicka, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.